Leisure Sitting Time Linked to Increased Risk of Malignancies in Women
the Cancer Therapy Advisor take:
Women with longer amounts of leisure-time spent sitting have a greater risk of total cancer, while no correlation was found between sitting time and men, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
Participants in this study included individuals who were initially cancer-free and enrolled in the American Cancer Society Cancer Prevention Study II Nutrition Cohort (from 1992 to 2009). Of 69,260 men, 18,555 were diagnosed with cancer, compared to 12,236 women diagnosed out of 77,462.
The authors adjusted the data for physical activity, BMI, and other factors—noting that physical activity was independent of sitting time.
Results showed that longer sitting time was associated with malignancy in women (relative risks (RR) = 1.10; 95% CI: 1.04, 1.17 for >6 hours vs. <3 hours/day), but not in men (RR=1.00; 95% CI: 0.96, 1.05).
Women with greater levels of leisure-time spent sitting were at greater risk for developing site-specific cancers such as multiple myeloma (RR=1.65; 95% CI: 1.07, 2.54), invasive breast cancer (RR=1.10; 95% CI: 1.00, 1.21), and ovarian cancer (RR=1.43; 95% CI: 1.10, 1.87).
The study suggests further research be conducted regarding the different correlations between men and women. Furthermore, it supports the American Cancer Society’s recommendation to reduce leisure-time spent sitting whenever possible.
Women with longer amounts of leisure-time spent sitting have a greater risk of total cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Plastics and Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer